optimizerx partners with pharmaceutical companies to offer electronic versions of their patient savings and support materials within the eprescribing workflow of leading electronic health record platforms. using the samplemd technology, providers can more efficiently distribute savings and support materials to their patients. the ecoupon technology, available in the eprescribing workflow of over 300,000+ providers, has expanded the distribution of savings and support materials to millions of patients throughout the us and aims to increase adherence rates and affordability of prescribed medications. about optimizerx corp. optimizerx corp. provides unique consumer and physician platforms to help patients better afford and comply with their medications, while offering pharmaceutical companies effective ways to expand awareness, affordability and adherence to their brands. for more information on samplemd, please call us at (877) 568-3840 or visit www.samplemd.com.
Company profile
Ticker
OPRX
Exchange
Website
CEO
William J. Febbo
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Healthy Offers, Inc. • CareSpeak Communications, Inc. • CareSpeak Communications, d.o.o. • Cyberdiet, a controlled foreign corporation incorporated ...
IRS number
261265381
OPRX stock data
Latest filings (excl ownership)
8-K
OptimizeRx Reports Strong Fourth Quarter and Full Year 2023 Financial Results
18 Apr 24
10-K
2023 FY
Annual report
15 Apr 24
8-K
Entry into a Material Definitive Agreement
2 Apr 24
NT 10-K
Notice of late annual filing
28 Mar 24
8-K
OptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023
11 Mar 24
8-K
OptimizeRx Announces Strategic Board Changes to Support Growth and Evolving Landscape
26 Jan 24
8-K/A
Financial Statements and Exhibits
5 Jan 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
OptimizeRx Reports Third Quarter 2023 Financial Results
6 Nov 23
8-K
Entry into a Material Definitive Agreement
25 Oct 23
Transcripts
OPRX
Earnings call transcript
2023 Q4
28 Mar 24
OPRX
Earnings call transcript
2023 Q3
6 Nov 23
OPRX
Earnings call transcript
2023 Q2
14 Aug 23
OPRX
Earnings call transcript
2023 Q1
10 May 23
OPRX
Earnings call transcript
2022 Q4
8 Mar 23
OPRX
Earnings call transcript
2022 Q3
9 Nov 22
OPRX
Earnings call transcript
2022 Q2
10 Aug 22
OPRX
Earnings call transcript
2022 Q1
5 May 22
OPRX
Earnings call transcript
2021 Q4
25 Feb 22
OPRX
Earnings call transcript
2021 Q3
10 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 9.92 mm | 9.92 mm | 9.92 mm | 9.92 mm | 9.92 mm | 9.92 mm |
Cash burn (monthly) | (no burn) | 2.62 mm | 1.18 mm | 1.36 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | 18.04 mm | 8.17 mm | 9.40 mm | n/a | n/a |
Cash remaining | n/a | -8.12 mm | 1.76 mm | 521.69 k | n/a | n/a |
Runway (months of cash) | n/a | -3.1 | 1.5 | 0.4 | n/a | n/a |
Institutional ownership, Q3 2023
71.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 94 |
Opened positions | 15 |
Closed positions | 24 |
Increased positions | 24 |
Reduced positions | 31 |
13F shares | Current |
---|---|
Total value | 99.69 bn |
Total shares | 13.07 mm |
Total puts | 50.10 k |
Total calls | 116.90 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
First Light Asset Management | 2.49 mm | $19.34 bn |
BLK Blackrock | 1.10 mm | $8.57 bn |
Vanguard | 992.59 k | $7.72 bn |
Blair William & Co | 836.50 k | $6.51 bn |
AWM Investment | 782.57 k | $6.09 bn |
D. E. Shaw & Co. | 600.39 k | $4.67 bn |
Kennedy Capital Management | 555.68 k | $4.32 bn |
STT State Street | 485.82 k | $3.78 bn |
Rice Hall James & Associates | 387.38 k | $3.01 bn |
G2 Investment Partners Management | 371.47 k | $2.89 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Apr 24 | William J Febbo | Common Stock | Grant | Acquire A | No | No | 0 | 60,000 | 0.00 | 538,144 |
15 Mar 24 | Stephen L Silvestro | Common Stock | Grant | Acquire A | No | No | 0 | 7,750 | 0.00 | 13,706 |
15 Feb 24 | William J Febbo | Common Stock | Grant | Acquire A | No | No | 0 | 15,000 | 0.00 | 553,144 |
15 Feb 24 | Doug Besch | Common Stock | Grant | Acquire A | No | No | 0 | 4,000 | 0.00 | 7,848 |
15 Feb 24 | Marion Odence-Ford | Common Stock | Grant | Acquire A | No | No | 0 | 4,267 | 0.00 | 18,498 |
News
JMP Securities Reiterates Market Outperform on OptimizeRx, Maintains $15 Price Target
16 Apr 24
OptimizeRx Q4 Adj EPS $0.26, Inline, Sales $28.40M Beat $26.47M Estimate
16 Apr 24
JMP Securities Initiates Coverage On OptimizeRx with Market Outperform Rating, Announces Price Target of $15
4 Apr 24
Where OptimizeRx Stands With Analysts
1 Apr 24
Stifel Maintains Buy on OptimizeRx, Maintains $13 Price Target
1 Apr 24
Press releases
OptimizeRx Releases 2024 Environmental, Social, and Governance (ESG) Report
18 Apr 24
OptimizeRx Named America's Fastest-Growing Company for Fifth Year in a Row
11 Apr 24
OptimizeRx Sets Fourth Quarter 2023 Conference Call for March 28, 2024 at 8:30 a.m. ET
25 Mar 24
OptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023
11 Mar 24
OptimizeRx Powers Walmart's 'Specialty Pharmacies of the Community' Outreach Effort
4 Mar 24